Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy in first-line metastatic non-small cell lung cancer
MOH_2022-03-02_010647Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing MK-7684A plus chemotherapy with Pembrolizumab plus chemotherapy (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Jan 2022; status: active, not recruiting.
02
Drugs
vibostolimab + pembrolizumabpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2022-03-02_010647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-03-02_010647.